We are live on ! Find out more
AZN icon

AstraZeneca

1,516 hedge funds and large institutions have $198B invested in AstraZeneca in 2026 Q2 according to their latest regulatory filings, with 265 funds opening new positions, 528 increasing their positions, 499 reducing their positions, and 123 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more capital inflows, than outflows

Capital inflows: $19.7B | Capital outflows: $5.62B

115% more first-time investments, than exits

New positions opened: 265 | Existing positions closed: 123

9% more funds holding

Funds holding: 1,392 → 1,516 (+124)

3.9% more ownership

Funds ownership: 48.84% → 52.74% (+3.9%)

6% more repeat investments, than reductions

Existing positions increased: 528 | Existing positions reduced: 499

17% less funds holding in top 10

Funds holding in top 10: 72 → 60 (-12)

42% less call options, than puts

Call options by funds: $704M | Put options by funds: $1.21B

Holders
1,516
Holders Change
+124
Holders Change %
+8.91%
% of All Funds
18.05%
Holding in Top 10
60
Holding in Top 10 Change
-12
Holding in Top 10 Change %
-16.67%
% of All Funds
0.71%
New
265
Increased
528
Reduced
499
Closed
123
Calls
$704​M
Puts
$1.21​B
Net Calls
-⁠$507​M
Net Calls Change
+$89.2​M

AZN Hedge Fund Activity: Q2 2026 in Review

1,516 of the 8,401 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q2 2026, worth a combined $198B — up 31% from $152B a quarter earlier.

Buyers outnumbered sellers: 265 funds opened new AZN positions and 123 closed out — a net gain of 142 holders — while 528 added to existing stakes and 499 trimmed.

The largest buyer was Royal Bank of Canada, adding an estimated $1.97B. The largest seller was T. Rowe Price Associates, cutting an estimated $540M.

  • 1,516 institutional investors held AstraZeneca (AZN) as of Q2 2026, up from 1,392 in Q1 2026.
  • Funds reported $198B of AstraZeneca stock for Q2 2026, up 31% quarter-over-quarter.
  • 265 funds opened new AstraZeneca positions in Q2 2026 and 123 closed out, a net change of +142 holders.
  • The largest AstraZeneca buyer in Q2 2026 was Royal Bank of Canada, an estimated $1.97B added.
  • The largest AstraZeneca seller in Q2 2026 was T. Rowe Price Associates, an estimated $540M sold.

Based on aggregated 13F filings for Q2 2026.